Answers are grounded in this paper and cite their sources.
Exploring metal phosphonates with new crystal structures is of significance for the development of metal-organic frameworks (MOFs). In this work, two new copper phosphonates, [tetraauqa-1,4-phenylenebis(hydroxymethylene))bisphosphonate biscopper(II)] bishydrate [Cu2(H2L)(H2O)4]·2H2O (1) and 1,4-phenylenebis(hydroxymethylene))bisphosphonate-(4,4'-bipy) copper(II) [Cu(H4L)(4,4'-bipy)] (2) (4,4'-bipy = 4,4'-bipyridine), have been synthesized from a hydroxy functionalized bisphosphonate ligand, H6L = (1,4-phenylenebis(hydroxymethylene))bis(phosphonic acid). The introduction of a hydroxy group can regulate the crystal structures. The bisphosphonate ligand in 1 is hexadentate, binding six copper ions with its six phosphonate oxygen atoms and two hydroxy oxygen atoms, forming a three-dimensional framework structure with rectangle channels running along the b-direction. For 2, the bisphosphonate ligands are double deprotonated and chelate or bridge two copper ions, showing a two-dimensional layered crystal structure. These compounds have interesting fluorescence properties with emission maxima (307 and 410 nm) lying in the blue region.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: